OA11515A - Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists. - Google Patents

Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists. Download PDF

Info

Publication number: OA11515A
Authority: OA; OAPI
Prior art keywords: compound; alkyl; formula; group; aryl
Prior art date: 1997-05-23

Application number

OA9900253A

Other languages

English (en)

Inventor

Giusoppe Arnaldo Mari Giardina

Mario Grugni

Davide Graziani

Francesco Ravegliaiuca

Original Assignee

Smithkline Beecham Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-23

Filing date

1999-11-23

Publication date

2004-02-04

1997-05-23 Priority claimed from GBGB9710750.2A external-priority patent/GB9710750D0/en

1997-10-17 Priority claimed from IT002354 external-priority patent/IT1295358B1/it

1997-12-16 Priority claimed from ITMI972775 external-priority patent/IT1296976B1/it

1999-11-23 Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa

2004-02-04 Publication of OA11515A publication Critical patent/OA11515A/en

Links

108010040722 Neurokinin-2 Receptors Proteins 0.000 title claims description 6
108010040716 Neurokinin-3 Receptors Proteins 0.000 title claims description 5
102100029409 Neuromedin-K receptor Human genes 0.000 title description 7
102100037342 Substance-K receptor Human genes 0.000 title description 3
239000002464 receptor antagonist Substances 0.000 title description 2
229940044551 receptor antagonist Drugs 0.000 title description 2
LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical class C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 190
-1 cyano, carboxy Chemical group 0.000 claims abstract description 34
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 22
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 22
125000003118 aryl group Chemical group 0.000 claims abstract description 21
239000001257 hydrogen Substances 0.000 claims abstract description 18
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
125000001424 substituent group Chemical group 0.000 claims abstract description 13
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 12
125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
125000005842 heteroatom Chemical group 0.000 claims abstract description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 7
229910052736 halogen Inorganic materials 0.000 claims abstract description 7
150000002367 halogens Chemical class 0.000 claims abstract description 7
229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
125000003107 substituted aryl group Chemical group 0.000 claims abstract description 7
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims abstract description 6
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
125000000278 alkyl amino alkyl group Chemical group 0.000 claims abstract description 5
229910052799 carbon Inorganic materials 0.000 claims abstract description 5
238000004519 manufacturing process Methods 0.000 claims abstract description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
125000004945 acylaminoalkyl group Chemical group 0.000 claims abstract description 3
125000004423 acyloxy group Chemical group 0.000 claims abstract description 3
125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 3
125000005518 carboxamido group Chemical group 0.000 claims abstract description 3
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 3
125000005544 phthalimido group Chemical group 0.000 claims abstract description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims description 35
238000000034 method Methods 0.000 claims description 29
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
125000000753 cycloalkyl group Chemical group 0.000 claims description 11
230000000694 effects Effects 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 10
125000003545 alkoxy group Chemical group 0.000 claims description 9
230000008569 process Effects 0.000 claims description 9
125000003710 aryl alkyl group Chemical group 0.000 claims description 7
125000006413 ring segment Chemical group 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
125000003282 alkyl amino group Chemical group 0.000 claims description 4
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
125000001188 haloalkyl group Chemical group 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
206010011953 Decreased activity Diseases 0.000 claims description 3
206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 3
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
125000004043 oxo group Chemical group O=* 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
208000024891 symptom Diseases 0.000 claims description 3
125000002837 carbocyclic group Chemical group 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
125000004093 cyano group Chemical group *C#N 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 14
239000003814 drug Substances 0.000 abstract description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 abstract 1
125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
239000000203 mixture Substances 0.000 description 35
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
208000035475 disorder Diseases 0.000 description 24
238000006243 chemical reaction Methods 0.000 description 23
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 15
239000002904 solvent Substances 0.000 description 14
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
235000019439 ethyl acetate Nutrition 0.000 description 12
201000010099 disease Diseases 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
229960001866 silicon dioxide Drugs 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
239000003480 eluent Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
239000007921 spray Substances 0.000 description 9
239000007832 Na2SO4 Substances 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
229910052938 sodium sulfate Inorganic materials 0.000 description 8
235000011152 sodium sulphate Nutrition 0.000 description 8
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 7
235000011114 ammonium hydroxide Nutrition 0.000 description 7
239000007789 gas Substances 0.000 description 7
239000012044 organic layer Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
229910052786 argon Inorganic materials 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
201000004624 Dermatitis Diseases 0.000 description 5
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 5
101800002813 Neurokinin-B Proteins 0.000 description 5
208000002193 Pain Diseases 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
230000002496 gastric effect Effects 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
208000033808 peripheral neuropathy Diseases 0.000 description 5
239000007787 solid Substances 0.000 description 5
208000024827 Alzheimer disease Diseases 0.000 description 4
208000019695 Migraine disease Diseases 0.000 description 4
102000046798 Neurokinin B Human genes 0.000 description 4
102100024304 Protachykinin-1 Human genes 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
239000000010 aprotic solvent Substances 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
239000013256 coordination polymer Substances 0.000 description 4
239000010779 crude oil Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
239000003446 ligand Substances 0.000 description 4
206010027599 migraine Diseases 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
125000004193 piperazinyl group Chemical group 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
208000017520 skin disease Diseases 0.000 description 4
238000003756 stirring Methods 0.000 description 4
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
101000655188 Homo sapiens Tachykinin-3 Proteins 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 3
101800000399 Neurokinin A Proteins 0.000 description 3
102400000097 Neurokinin A Human genes 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
101800003906 Substance P Proteins 0.000 description 3
102000003141 Tachykinin Human genes 0.000 description 3
102100033009 Tachykinin-3 Human genes 0.000 description 3
206010046543 Urinary incontinence Diseases 0.000 description 3
208000024780 Urticaria Diseases 0.000 description 3
239000000556 agonist Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000012043 crude product Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000002825 functional assay Methods 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
238000003328 mesylation reaction Methods 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
201000001119 neuropathy Diseases 0.000 description 3
230000007823 neuropathy Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
125000003003 spiro group Chemical group 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
108060008037 tachykinin Proteins 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
ZSVACLAZDFXWQG-UHFFFAOYSA-N 3-methyl-2-phenylquinoline-4-carboxylic acid Chemical compound N1=C2C=CC=CC2=C(C(O)=O)C(C)=C1C1=CC=CC=C1 ZSVACLAZDFXWQG-UHFFFAOYSA-N 0.000 description 2
YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
FJUPUBXRHPSANV-UHFFFAOYSA-N 4-hydroxy-1-phenylbutan-1-one Chemical compound OCCCC(=O)C1=CC=CC=C1 FJUPUBXRHPSANV-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
206010065040 AIDS dementia complex Diseases 0.000 description 2
206010002027 Amyotrophy Diseases 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
208000027932 Collagen disease Diseases 0.000 description 2
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
208000016192 Demyelinating disease Diseases 0.000 description 2
206010012335 Dependence Diseases 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
201000010374 Down Syndrome Diseases 0.000 description 2
208000030814 Eating disease Diseases 0.000 description 2
208000019454 Feeding and Eating disease Diseases 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
101000600912 Homo sapiens Substance-K receptor Proteins 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
208000016285 Movement disease Diseases 0.000 description 2
208000007920 Neurogenic Inflammation Diseases 0.000 description 2
102000002003 Neurokinin-3 Receptors Human genes 0.000 description 2
102000003797 Neuropeptides Human genes 0.000 description 2
108090000189 Neuropeptides Proteins 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
206010039710 Scleroderma Diseases 0.000 description 2
208000034189 Sclerosis Diseases 0.000 description 2
206010039966 Senile dementia Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
206010044688 Trisomy 21 Diseases 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000036428 airway hyperreactivity Effects 0.000 description 2
230000007815 allergy Effects 0.000 description 2
239000004411 aluminium Substances 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
235000019400 benzoyl peroxide Nutrition 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
125000000068 chlorophenyl group Chemical group 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
229960004132 diethyl ether Drugs 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
235000014632 disordered eating Nutrition 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
208000024732 dysthymic disease Diseases 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
208000004296 neuralgia Diseases 0.000 description 2
239000002746 neurokinin 2 receptor antagonist Substances 0.000 description 2
230000002981 neuropathic effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
230000020341 sensory perception of pain Effects 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
230000002455 vasospastic effect Effects 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
HMHYXLVEFVGOPM-QKUYTOGTSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutan Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C1=CC=CC=C1 HMHYXLVEFVGOPM-QKUYTOGTSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
AQFLVLHRZFLDDV-UHFFFAOYSA-N 1-phenylpropan-1-amine Chemical compound CCC(N)C1=CC=CC=C1 AQFLVLHRZFLDDV-UHFFFAOYSA-N 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
OFULFJVKVDJWPT-UHFFFAOYSA-N 2-phenyl-3-[2-(4-phenylpiperazin-1-yl)ethyl]quinoline-4-carboxylic acid Chemical compound C=1C=CC=CC=1C1=NC2=CC=CC=C2C(C(=O)O)=C1CCN(CC1)CCN1C1=CC=CC=C1 OFULFJVKVDJWPT-UHFFFAOYSA-N 0.000 description 1
PSNBBHGLUVIFNX-LMOVPXPDSA-N 3-[(2s)-2-methoxycarbonylpyrrolidin-1-yl]-2-phenylquinoline-4-carboxylic acid;hydrochloride Chemical compound Cl.COC(=O)[C@@H]1CCCN1C1=C(C=2C=CC=CC=2)N=C(C=CC=C2)C2=C1C(O)=O PSNBBHGLUVIFNX-LMOVPXPDSA-N 0.000 description 1
IYTJRMRETHPZAC-UHFFFAOYSA-N 4,4-dibenzylpiperidine Chemical compound C1CNCCC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 IYTJRMRETHPZAC-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
USQOVYLRWBOSQC-HNNXBMFYSA-N CCCCCCNC(=O)Oc1cccc(c1)-c1ccc(cc1F)[C@H](C)C(O)=O Chemical compound CCCCCCNC(=O)Oc1cccc(c1)-c1ccc(cc1F)[C@H](C)C(O)=O USQOVYLRWBOSQC-HNNXBMFYSA-N 0.000 description 1
101150018198 COX1 gene Proteins 0.000 description 1
101150043980 COXI gene Proteins 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
241001327708 Coriaria sarmentosa Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
238000005684 Liebig rearrangement reaction Methods 0.000 description 1
101150079116 MT-CO1 gene Proteins 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
238000006153 Pfitzinger synthesis reaction Methods 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000350158 Prioria balsamifera Species 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
208000013007 Rodent disease Diseases 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010072901 Tachykinin Receptors Proteins 0.000 description 1
102000007124 Tachykinin Receptors Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 description 1
JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
235000010210 aluminium Nutrition 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001733 carboxylic acid esters Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
238000005661 deetherification reaction Methods 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000006275 fascioliasis Diseases 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical group C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
HQEIPVHJHZTMDP-JEDNCBNOSA-N methyl (2s)-pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@@H]1CCCN1 HQEIPVHJHZTMDP-JEDNCBNOSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000004492 methyl ester group Chemical group 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
239000002740 neurokinin 3 receptor antagonist Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
238000006053 organic reaction Methods 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000003380 propellant Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000004224 protection Effects 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
230000006340 racemization Effects 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000010992 reflux Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
108010016070 senktide Proteins 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000000967 suction filtration Methods 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
239000002466 tachykinin receptor agonist Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pulmonology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

OA9900253A 1997-05-23 1999-11-23 Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists. OA11515A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9710750.2A GB9710750D0 (en)	1997-05-23	1997-05-23	Novel compounds
IT002354 IT1295358B1 (it)	1997-10-17	1997-10-17	Derivati chinolinici procedimento per la loro preparazione e uso come antagonisti del recettore nk3
ITMI972775 IT1296976B1 (it)	1997-12-16	1997-12-16	Derivati chinolinici procedimento per la loro preparazione e uso come antagonisti del recettore nk3

Publications (1)

Publication Number	Publication Date
OA11515A true OA11515A (en)	2004-02-04

Family

ID=27268859

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900253A OA11515A (en)	1997-05-23	1999-11-23	Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists.

Country Status (26)

Country	Link
EP (1)	EP0983262B1 (fr)
JP (1)	JP2002500645A (fr)
CN (1)	CN1264378A (fr)
AP (1)	AP9901695A0 (fr)
AR (1)	AR012732A1 (fr)
AT (1)	ATE244711T1 (fr)
AU (1)	AU8209898A (fr)
BG (1)	BG104009A (fr)
BR (1)	BR9809652A (fr)
CA (1)	CA2291111A1 (fr)
CO (1)	CO4950515A1 (fr)
DE (1)	DE69816290T2 (fr)
DZ (1)	DZ2498A1 (fr)
EA (1)	EA199901062A1 (fr)
ES (1)	ES2201509T3 (fr)
HU (1)	HUP0002300A3 (fr)
ID (1)	ID22876A (fr)
IL (1)	IL133036A0 (fr)
MA (1)	MA26501A1 (fr)
NO (1)	NO995711L (fr)
OA (1)	OA11515A (fr)
PE (1)	PE75199A1 (fr)
PL (1)	PL336942A1 (fr)
SK (1)	SK159299A3 (fr)
TR (1)	TR199902883T2 (fr)
WO (1)	WO1998052942A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6780875B2 (en) *	1998-11-20	2004-08-24	Smithkline Beecham S.P.A.	Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
GB9825554D0 (en) *	1998-11-20	1999-01-13	Smithkline Beecham Spa	Novel Compounds
CN1406225A (zh) *	1998-11-20	2003-03-26	葛兰素史密丝克莱恩有限公司	用作nk－3和nk－2受体拮抗剂的喹啉－4－甲酰胺衍生物
WO2000058313A1 (fr)	1999-03-29	2000-10-05	Neurogen Corporation	Derives de quinoline 4-substitues en tant que ligands des recepteurs de gaba
AU4802500A (en)	1999-04-26	2000-11-10	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
WO2002013825A1 (fr) *	2000-08-11	2002-02-21	Smithkline Beecham P.L.C.	Nouvelle utilisation pharmaceutique de dérivés quinnoliniques
US20040082589A1 (en) *	2000-11-13	2004-04-29	Carlo Farina	Quinoline derivatives as nk-3 and nk-2 antagonists
WO2002044165A1 (fr) *	2000-11-28	2002-06-06	Glaxosmithkline Spa	Derives de quinoline utilises comme antagonistes de nk-3
GB0028964D0 (en) *	2000-11-28	2001-01-10	Smithkline Beecham Spa	Novel compounds
US6540733B2 (en)	2000-12-29	2003-04-01	Corazon Technologies, Inc.	Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
GB0109122D0 (en) *	2001-04-11	2001-05-30	Smithkline Beecham Spa	Novel compounds
US20040152726A1 (en) *	2001-04-11	2004-08-05	Carlo Farina	Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
MY134211A (en) *	2001-05-18	2007-11-30	Smithkline Beecham Corp	Novel use
GB0425076D0 (en) *	2004-11-12	2004-12-15	Smithkline Beecham Corp	Novel compounds
GB0425075D0 (en) *	2004-11-12	2004-12-15	Smithkline Beecham Corp	Novel compounds
GB0425077D0 (en) *	2004-11-12	2004-12-15	Smithkline Beecham Corp	Novel compounds
AU2006253054A1 (en) *	2005-06-03	2006-12-07	Astrazeneca Ab	Quinoline derivatives as NK3 anatgonists
GB0515580D0 (en)	2005-07-29	2005-09-07	Merck Sharp & Dohme	Therapeutic compounds
AR057130A1 (es)	2005-09-21	2007-11-14	Astrazeneca Ab	Quinolinas de alquilsulfoxido y una composicion farmaceutica
DE202007017299U1 (de) *	2007-12-12	2009-04-23	Drebo Werkzeugfabrik Gmbh	Bohrer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RO114445B1 (ro) *	1994-05-27	1999-04-30	Smithkline Beecham S.P.A.	Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
AR004735A1 (es) *	1995-11-24	1999-03-10	Smithkline Beecham Spa	Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.

1998
- 1998-05-18 ES ES98932069T patent/ES2201509T3/es not_active Expired - Lifetime
- 1998-05-18 AU AU82098/98A patent/AU8209898A/en not_active Abandoned
- 1998-05-18 AP APAP/P/1999/001695A patent/AP9901695A0/en unknown
- 1998-05-18 HU HU0002300A patent/HUP0002300A3/hu unknown
- 1998-05-18 BR BR9809652-4A patent/BR9809652A/pt not_active IP Right Cessation
- 1998-05-18 WO PCT/EP1998/003014 patent/WO1998052942A1/fr not_active Ceased
- 1998-05-18 SK SK1592-99A patent/SK159299A3/sk unknown
- 1998-05-18 EP EP98932069A patent/EP0983262B1/fr not_active Expired - Lifetime
- 1998-05-18 CN CN98807356A patent/CN1264378A/zh active Pending
- 1998-05-18 PL PL98336942A patent/PL336942A1/xx unknown
- 1998-05-18 JP JP54996798A patent/JP2002500645A/ja not_active Ceased
- 1998-05-18 DE DE69816290T patent/DE69816290T2/de not_active Expired - Fee Related
- 1998-05-18 AT AT98932069T patent/ATE244711T1/de not_active IP Right Cessation
- 1998-05-18 ID IDW991432A patent/ID22876A/id unknown
- 1998-05-18 IL IL13303698A patent/IL133036A0/xx unknown
- 1998-05-18 EA EA199901062A patent/EA199901062A1/ru unknown
- 1998-05-18 CA CA002291111A patent/CA2291111A1/fr not_active Abandoned
- 1998-05-18 TR TR1999/02883T patent/TR199902883T2/xx unknown
- 1998-05-19 DZ DZ980108A patent/DZ2498A1/fr active
- 1998-05-20 PE PE1998000398A patent/PE75199A1/es not_active Application Discontinuation
- 1998-05-21 MA MA25086A patent/MA26501A1/fr unknown
- 1998-05-21 AR ARP980102363A patent/AR012732A1/es not_active Application Discontinuation
- 1998-05-22 CO CO98029024A patent/CO4950515A1/es unknown
1999
- 1999-11-22 NO NO995711A patent/NO995711L/no not_active Application Discontinuation
- 1999-11-23 OA OA9900253A patent/OA11515A/en unknown
- 1999-12-14 BG BG104009A patent/BG104009A/xx unknown

Also Published As

Publication number	Publication date
EP0983262B1 (fr)	2003-07-09
NO995711D0 (no)	1999-11-22
ES2201509T3 (es)	2004-03-16
DZ2498A1 (fr)	2003-01-25
DE69816290D1 (de)	2003-08-14
EA199901062A1 (ru)	2000-08-28
MA26501A1 (fr)	2004-12-20
ID22876A (id)	1999-12-16
HUP0002300A2 (hu)	2001-06-28
HUP0002300A3 (en)	2002-01-28
AP9901695A0 (en)	1999-12-31
TR199902883T2 (xx)	2000-05-22
ATE244711T1 (de)	2003-07-15
AR012732A1 (es)	2000-11-08
BG104009A (en)	2000-07-31
EP0983262A1 (fr)	2000-03-08
PL336942A1 (en)	2000-07-17
PE75199A1 (es)	1999-10-22
IL133036A0 (en)	2001-03-19
WO1998052942A1 (fr)	1998-11-26
CN1264378A (zh)	2000-08-23
AU8209898A (en)	1998-12-11
CO4950515A1 (es)	2000-09-01
BR9809652A (pt)	2001-09-11
CA2291111A1 (fr)	1998-11-26
NO995711L (no)	2000-01-19
SK159299A3 (en)	2000-06-12
DE69816290T2 (de)	2004-05-27
JP2002500645A (ja)	2002-01-08

Publication	Publication Date	Title
US20070161647A1 (en)	2007-07-12	QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS
EP1377555B1 (fr)	2007-01-24	Un derive de dioxino[2,3-g]quinoline-9-acide carboxylique en tant qu'antagoniste du recepteur nk3
US20020068827A1 (en)	2002-06-06	Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists
EP0983262B1 (fr)	2003-07-09	Derives de quinoline-4-carboxamide comme antagonistes des recepteurs nk-2 et nk-3
WO2000031037A1 (fr)	2000-06-02	Derives de quinoline-4-carboxamide utilises comme antagonistes des recepteurs nk-3 et nk-2
EP1131294B1 (fr)	2006-12-20	Derives de quinoline utilises comme ligands des recepteurs nk-2 et nk-3
US20040077658A1 (en)	2004-04-22	Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
US20040082589A1 (en)	2004-04-29	Quinoline derivatives as nk-3 and nk-2 antagonists
US6780875B2 (en)	2004-08-24	Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
US20070197546A1 (en)	2007-08-23	Quinoline-4-carboxamide as nk-2 and nk-3 receptor antagonists
US20060094726A1 (en)	2006-05-04	Quinoline derivatives as nk-2 and nk-3 receptor antagonists
US20040180902A1 (en)	2004-09-16	3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
KR20010012823A (ko)	2001-02-26	Ｎｋ-2 및 ｎｋ-3 수용체 길항제로서의퀴놀린-4-카르복스아미드 유도체
MXPA99010841A (en)	2000-07-01	Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
CZ416199A3 (cs)	2000-08-16	Chinolin-4-karboxamidové deriváty jako antagonisté receptoru pro NK-2 a NK-3
ITMI972352A1 (it)	1999-04-17	Derivati chinolinici, procedimento per la loro preparazione e uso come antagonisti del recettore nk3